DB:SCP

Stock Analysis Report

Executive Summary

Scancell Holdings plc engages in the discovery and development of novel vaccines for the treatment of various cancers.


Snowflake Analysis

Excellent balance sheet and overvalued.

Share Price & News

How has Scancell Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SCP's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

16.3%

SCP

11.3%

DE Biotechs

7.1%

DE Market


1 Year Return

-19.0%

SCP

-5.1%

DE Biotechs

-17.5%

DE Market

Return vs Industry: SCP underperformed the German Biotechs industry which returned -1.2% over the past year.

Return vs Market: SCP underperformed the German Market which returned -14.1% over the past year.


Shareholder returns

SCPIndustryMarket
7 Day16.3%11.3%7.1%
30 Day-34.7%-8.0%-20.0%
90 Day-35.1%-22.7%-26.1%
1 Year-19.0%-19.0%-4.9%-5.1%-15.0%-17.5%
3 Year-68.7%-68.7%17.7%16.4%-18.8%-25.8%
5 Year-84.2%-84.2%-5.1%-7.5%-17.9%-29.2%

Price Volatility Vs. Market

How volatile is Scancell Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Scancell Holdings undervalued compared to its fair value and its price relative to the market?

2.23x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SCP's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SCP's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SCP is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: SCP is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SCP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SCP is good value based on its PB Ratio (2.2x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Scancell Holdings forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

4.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SCP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SCP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SCP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if SCP's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if SCP's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SCP's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Scancell Holdings performed over the past 5 years?

-20.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SCP is currently unprofitable.

Growing Profit Margin: SCP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SCP is unprofitable, and losses have increased over the past 5 years at a rate of -20.1% per year.

Accelerating Growth: Unable to compare SCP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SCP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: SCP has a negative Return on Equity (-45.91%), as it is currently unprofitable.


Next Steps

Financial Health

How is Scancell Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: SCP's short term assets (£8.0M) exceed its short term liabilities (£778.3K).

Long Term Liabilities: SCP has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: SCP is debt free.

Reducing Debt: SCP has not had any debt for past 5 years.


Balance Sheet

Inventory Level: SCP has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if SCP's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SCP has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SCP has less than a year of cash runway if free cash flow continues to reduce at historical rates of -20.8% each year


Next Steps

Dividend

What is Scancell Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SCP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SCP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SCP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SCP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SCP's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Cliff Holloway

2.17s

Tenure

UK£250,000

Compensation

Dr. Clifford Holloway, also known as Cliff, BPharm, Ph.D., is the Chief Executive Officer of Scancell Holdings Plc since January 10, 2018 and also serves as its Director. Dr. Holloway was the Chief Busines ...


CEO Compensation Analysis

Compensation vs Market: Cliff's total compensation ($USD310.31K) is about average for companies of similar size in the German market ($USD429.96K).

Compensation vs Earnings: Cliff's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Clifford Holloway
CEO & Director2.17yrsUK£250.00kno data
Lindy Durrant
Chief Scientific Officer & Director11.92yrsUK£175.00k2.24% £596.0k
Sally Adams
Development Director & Directorno dataUK£193.13k0.013% £3.5k
Keith Green
Director of Finance & Administration3.5yrsno datano data
Samantha Paston
Head of Research1.17yrsno datano data
Adrian Parry
Head of Manufacturing1.08yrsno datano data

2.2yrs

Average Tenure

Experienced Management: SCP's management team is considered experienced (2.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Clifford Holloway
CEO & Director2.17yrsUK£250.00kno data
Lindy Durrant
Chief Scientific Officer & Director11.92yrsUK£175.00k2.24% £596.0k
Sally Adams
Development Director & Directorno dataUK£193.13k0.013% £3.5k
Richard Goodfellow
Director11.92yrsUK£145.83k1.42% £377.0k
John Chiplin
Non-Executive Chairman4.17yrsUK£50.00k0.43% £114.2k
Alan Lewis
Senior Independent Directorno dataUK£25.83kno data
Ursula Ney
Non-Executive Director0.42yrno datano data
Martin Diggle
Non-Executive Director0.75yrno datano data

4.2yrs

Average Tenure

60yo

Average Age

Experienced Board: SCP's board of directors are considered experienced (4.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.5%.


Top Shareholders

Company Information

Scancell Holdings plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Scancell Holdings plc
  • Ticker: SCP
  • Exchange: DB
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£23.733m
  • Listing Market Cap: UK£26.569m
  • Shares outstanding: 465.36m
  • Website: https://www.scancell.co.uk

Number of Employees


Location

  • Scancell Holdings plc
  • John Eccles House
  • Robert Robinson Avenue
  • Oxford
  • Oxfordshire
  • OX4 4GP
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SCLPAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPSep 2008
SCNL.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDSep 2008
SCPDB (Deutsche Boerse AG)YesOrdinary SharesDEEURSep 2008

Biography

Scancell Holdings plc engages in the discovery and development of novel vaccines for the treatment of various cancers. The company’s product candidates include SCIB1, which completed phase II clinical trial for the treatment of metastatic melanoma; SCIB2 that is in phase I/II combination trials for the treatment of non-small cell lung cancer; and Modi-1, which is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2 that is in pre-clinical trial for the treatment of multiple solid tumors. Scancell Holdings plc has a research collaboration agreement with BioNTech to develop T-cell receptor based therapeutics; and licensing and collaboration agreement with ISA Pharmaceuticals B.V. to use ISA’s AMPLIVANT adjuvant technology for the development and commercialization of Modi-1. The company was founded in 1997 and is based in Oxford, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/28 23:35
End of Day Share Price2020/03/27 00:00
Earnings2019/10/31
Annual Earnings2019/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.